Gina Tomaine

News

Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide for ALL

09/20/2022

Busulfan plus cyclophosphamide demonstrated noninferior efficiency and safety compared with total body irradiation plus cyclophosphamide for adult patients with standard-risk B-cell ALL in a phase 3 trial.

Busulfan plus cyclophosphamide...

09/20/2022

Oncology

News

Novel, Minimally Invasive Test Detects Higher Frequency of EZH2 Mutations in Follicular Lymphoma

11/14/2022

Gina Tomaine ;

Parallel testing of both tissue and liquid biopsy samples detects a higher frequency of EZH2 mutations in patients with follicular lymphoma, with significant clinical implications, according to a recent study.

Parallel testing of both tissue...

11/14/2022

Oncology

News

Fixed Duration Venetoclax Plus Rituximab Provides Long-Term Benefit vs Bendamustine Plus Rituximab in CLL

11/15/2022

Gina Tomaine ;

Benefits associated with venetoclax-rituximab on the phase 3 MURANO trial were maintained at 3 years following treatment cessation in patients with relapsed/refractory CLL, according to an update published in Blood.

Benefits associated with...

11/15/2022

Oncology

News

Transfusion Burden Decrease, Hemoglobin Increase With Luspatercept vs Epoetin Alfa Treatment for ESA‑Naive Patients With Transfusion‑Dependent Lower‑Risk MDS

09/08/2023

Gina Tomaine ;

Luspatercept demonstrated multiple clinical benefits for ESA-naive patients with transfusion-dependent lower-risk MDS, including hemoglobin increases and transfusion-burden decreases, according to research presented at the SOHO 2023 Annual...

Luspatercept demonstrated...

09/08/2023

Oncology

News

Brentuximab Vedotin Plus AVD Demonstrates Efficacy, Safety in Hodgkin Lymphoma: BREACH Trial

08/17/2022

Gina Tomaine ;

For patients with early stage unfavorable Hodgkin lymphoma, brentuximab vedotin combined with AVD was associated with an improved rate of PET negativity vs standard ABVD in a phase 2 trial.

For patients with early stage...

08/17/2022

Oncology

News

Odronextamab Demonstrates Promising Safety, Response in R/R Non-Hodgkin Lymphoma

11/17/2022

Gina Tomaine ;

CD20-CD3 bispecific antibody odronextamab showed a manageable safety profile and encouraging preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, according to a recent phase 1 study.

CD20-CD3 bispecific antibody...

11/17/2022

Oncology

News

FDA Approves Ibrutinib for Pediatric Patients With Chronic GVHD

08/25/2022

Gina Tomaine ;

The FDA granted expedited approval to ibrutinib for pediatric patients with chronic GVHD after failure of 1 or more lines of systemic therapy.

The FDA granted expedited...

08/25/2022

Oncology

News

Switching From Reference Trastuzumab to Biosimilar for HER2 Positive Breast Cancer May Not Affect Infusion Reaction, Cardiac Dysfunction

07/10/2023

Gina Tomaine ;

Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.

Switching from reference...

07/10/2023

Oncology

News

FDA Approves Brentuximab Vedotin Plus Chemotherapy for Pediatric Patients With Classical Hodgkin Lymphoma

11/17/2022

Gina Tomaine ;

The FDA granted approval to brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high-risk classical Hodgkin...

The FDA granted approval to...

11/17/2022

Oncology

News

Tacrolimus and Reduced-Dose Methotrexate Combined With Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease

09/28/2023

Gina Tomaine ;

Tacrolimus plus a reduced-dose of methotrexate combined with mycophenolate for GVHD prevention demonstrated a more favorable toxicity profile compared with the standard-of-care, according to a phase 3 trial.

Tacrolimus plus a reduced-dose...

09/28/2023

Oncology